Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 5/20 | 0.44 |
| ▸ | CHUK | O15111 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BMI1 | P35226 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837045 | 0.88 | IKBKB (0.44) | HTR2CIKBKBCHUKTOP2A | |
| SCHEMBL2818464 | 0.87 | HTR2C (0.47) | HTR2CIKBKBCHUKTOP2AKDM4E | |
| SCHEMBL2816677 | 0.86 | HTR2C (0.51) | HTR2CIKBKBCHUKTOP2AADORA2A | |
| SCHEMBL2815052 | 0.84 | HTR2C (0.47) | HTR2CIKBKBCHUKTOP2AADORA2A | |
| SCHEMBL2816389 | 0.84 | HTR2C (0.47) | HTR2CIKBKBCHUKTOP2AADORA2A | |
| SCHEMBL2818724 | 0.84 | IKBKB (0.48) | HTR2CIKBKBCHUKTOP2AADORA2A | |
| SCHEMBL2820522 | 0.84 | IKBKB (0.46) | IKBKBCHUKADORA2A | |
| SCHEMBL2817059 | 0.82 | MAPT (0.47) | HTR2CIKBKBCHUKTOP2AADORA2A | |
| SCHEMBL2816951 | 0.81 | HTR2C (0.44) | HTR2CIKBKBCHUKTOP2AADORA2A | |
| SCHEMBL2813932 | 0.81 | MAPT (0.51) | HTR2CIKBKBCHUKTOP2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | HTR2C 1292/4885IKBKB 855/4885CHUK 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.